Innate Pharma (IPHYF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -23,250 | 3,601 | -54,690 | 13,987 | -7,442 |
| Depreciation Amortization | 18,513 | 8,741 | 4,965 | 3,611 | 2,946 |
| Other Working Capital | 45,074 | -71,550 | -19,193 | -56,202 | 234,692 |
| Other Operating Activity | -1,222 | 20,789 | 14,595 | -2,176 | 524 |
| Operating Cash Flow | $39,115 | $-38,419 | $-54,322 | $-40,779 | $230,720 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | 3,193 | 3,507 | 68,538 | -86,645 |
| PPE Investments | -1,435 | -1,203 | -3,350 | -1,494 | -8,209 |
| Sale Of Investment | 2,240 | 25,407 | 14,411 | 8,624 | N/A |
| Purchase Sale Intangibles | -71,826 | -657 | -3,461 | -8,900 | N/A |
| Other Investing Activity | -69,734 | 1,277 | -47,867 | -8,708 | -40,859 |
| Investing Cash Flow | $-68,928 | $28,674 | $-33,299 | $66,960 | $-135,713 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 15,568 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 73,976 | 74,011 | 555 | 214 | 3,881 |
| Other Financing Activity | -2,447 | -1,708 | 479 | -880 | -516 |
| Financing Cash Flow | $87,097 | $72,303 | $1,034 | $-666 | $3,365 |
| Exchange Rate Effect | 6 | -31 | 77 | -26 | -70 |
| Beginning Cash Position | 170,592 | 117,352 | 198,827 | 169,166 | 71,338 |
| End Cash Position | 227,233 | 179,883 | 112,315 | 194,658 | 169,640 |
| Net Cash Flow | $56,641 | $62,499 | $-86,512 | $25,492 | $98,302 |
| Free Cash Flow | |||||
| Operating Cash Flow | 39,115 | -38,419 | -54,322 | -40,779 | 230,720 |
| Capital Expenditure | -1,424 | -1,229 | -3,350 | -1,494 | -8,209 |
| Free Cash Flow | 37,691 | -39,649 | -57,672 | -42,273 | 222,511 |